- Home
- GITS vs NXL Comparison
GITS vs NXL Comparison
Compare GITS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | NXL |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | South Korea | United States |
| Employees | N/A | 7 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | NXL |
|---|---|---|
| Price | $2.64 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 110.3K | ★ 200.4K |
| Earning Date | 11-12-2025 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.36 |
| 52 Week High | $7.09 | $2.57 |
Technical Indicators
Market Signals| Indicator | GITS | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 33.91 |
| Support Level | $2.13 | $0.37 |
| Resistance Level | $3.03 | $0.62 |
| Average True Range (ATR) | 0.37 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 56.96 | 21.73 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.